Back to Stakeholders

Canadian company providing clinical research services and therapist training for psychedelic-assisted therapies. Originally a psychedelic clinic operator, Numinus divested its US clinic assets in 2024 and reoriented as a contract research organisation (CRO) and training provider. Health Canada licensed to produce and analyse psilocybin.

Quick Facts

Type
Public Biotech
Ticker
TSX: NUMI
Website
Visit